Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Pfizer's Sloan Ratio for the quarter that ended in Dec. 2023 was 11.35%.
As of Dec. 2023, Pfizer has a Sloan Ratio of 11.35%, indicating there is a warning stage of accrual build up.
Pfizer Sloan Ratio % Historical Data
The historical data trend for Pfizer's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Pfizer's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pfizer's Sloan Ratio % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pfizer's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Pfizer's Sloan Ratio % falls into.
Pfizer Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Pfizer's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Pfizer's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was 5543 (Mar. 2023 ) + 2327 (Jun. 2023 ) + -2382 (Sep. 2023 ) + -3369 (Dec. 2023 ) = $2,119 Mil.
Pfizer's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was 1212 (Mar. 2023 ) + -1208 (Jun. 2023 ) + 3456 (Sep. 2023 ) + 5240 (Dec. 2023 ) = $8,700 Mil.
Pfizer's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was 3315 (Mar. 2023 ) + -25485 (Jun. 2023 ) + 888 (Sep. 2023 ) + -10996 (Dec. 2023 ) = $-32,278 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pfizer (NYSE:PFE) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2023, Pfizer has a Sloan Ratio of 11.35%, indicating there is a warning stage of accrual build up.
Pfizer Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Pfizer's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PFE has been successfully added to your 